<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211974</url>
  </required_header>
  <id_info>
    <org_study_id>Xuanwu-IMA</org_study_id>
    <nct_id>NCT04211974</nct_id>
  </id_info>
  <brief_title>Genomic Landscape of Intramedullary Astrocytoma</brief_title>
  <acronym>GIMA</acronym>
  <official_title>Genomic Landscape of Intramedullary Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      intramedullary astrocytoma is a rare and devastating spinal cord glioma. while the management
      of intracranial astrocytoma includes gross total resection, radiotherapy and chemotherapy,
      spinal cord astrocytoma is very difficult to be totally removed due to its infiltrative
      nature and unclear plane of dissection; Moreover, the use radiotherapy and chemotherapy for
      spinal cord astrocytoma is controversial. Therefore, the treatment for spinal cord
      astrocytoma is very limited as compared to its intracranial counterpart. Inadequate
      understanding of spinal cord astrocytoma mainly contribute to limited treatment, while the
      molecular profiling of intracranial astrocytoma is relatively well understood. Hence, we
      performed whole-exome sequencing of intramedullary astrocytoma aiming to identify the
      pathophysiological mechanisms underlying spinal cord astrocytoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intramedullary tumor only account for 2-4% of central nervous tumor. Of which, ependymoma and
      astrocytoma represent the most common intramedullary tumor. Although intramedullary
      astrocytoma is rare, it can cause significant mortality and morbidity. Different from its
      intracranial counterpart which can receive gross total resection and standard adjuvant
      treatment, intramedullary astrocytoma always cannot be removed completed due to its
      infiltrative nature and, additionally, radiotherapy and chemotherapy is controversial.
      Therefore, the treatment for this tumor is very limited. While the genetic profiling of
      intracranial astrocytoma is relatively well understood and standard treatment strategy has
      been developed, genetic alteration of intramedullary astrocytoma is less well understood.
      Identification of the molecular profiling can lead to well understanding of the
      pathophysiological mechanisms underlying intramedullary astrocytoma and more effective
      therapeutic strategy in future. Hence, we performed this study aiming to investigate the
      genetic profiling of intramedullary. All patients with intramedullary astrocytoma underwent
      surgery in our institution will be enrolled. Tumor tissue and matching blood will be obtained
      after the surgery. Whole-exome sequencing was performed on DNA extracted from these
      specimens. Moreover, demographic information, progress-free survival and overall survival
      will be evaluated in 3 year of follow-up after the initial diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>molecular profiling results</measure>
    <time_frame>1 month after the surgery</time_frame>
    <description>mutation identified via whole-exome sequencing will be recored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years after the diagnosis</time_frame>
    <description>overall survival of patients with spinal cord astrocytoma will be recorded;defined as the duration from the date of diagnosis to the date of final follow-up or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years after the diagnosis</time_frame>
    <description>progression free survival of patients with spinal cord astrocytoma will be recorded;was defined as the duration from the date of diagnosis to the date of tumor progression or death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Spinal Cord Astrocytoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>whole-exome sequencing</intervention_name>
    <description>Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.
whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumor resected and matched blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients who was histologically diagnosed as primary spinal cord astrocytoma or was
        suspected of primary spinal cord astrocytoma will be enrolled. But patiens who was
        suspected of primary spinal cord astrocytoma preoperatively but was confirmed as tumor
        rather than astrocytoma postoperatively via histology will be excluded.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients that histologically diagnosed as primary spinal cord astrocytoma

        Exclusion Criteria:

          -  patients with spinal cord tumors rather than astrocytoma

          -  metastatic astrocytoma

          -  tumor sample can not be obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengzeng Jian</last_name>
    <role>Study Director</role>
    <affiliation>Xuanwu Hospital, Capitial Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fengzeng Jiang, M.D.</last_name>
    <phone>+8613552067268</phone>
    <email>fengzengjiang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital, China International Neuroscience Institute, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Cheng, M.D.</last_name>
      <phone>+8613718690026</phone>
      <email>chenglei1865@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ogunlade J, Wiginton JG 4th, Elia C, Odell T, Rao SC. Primary Spinal Astrocytomas: A Literature Review. Cureus. 2019 Jul 26;11(7):e5247. doi: 10.7759/cureus.5247. Review.</citation>
    <PMID>31565645</PMID>
  </reference>
  <reference>
    <citation>Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166.</citation>
    <PMID>29118226</PMID>
  </reference>
  <reference>
    <citation>Guss ZD, Moningi S, Jallo GI, Cohen KJ, Wharam MD, Terezakis SA. Management of pediatric spinal cord astrocytomas: outcomes with adjuvant radiation. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1307-11. doi: 10.1016/j.ijrobp.2012.11.022. Epub 2013 Feb 20.</citation>
    <PMID>23433793</PMID>
  </reference>
  <reference>
    <citation>Kim WH, Yoon SH, Kim CY, Kim KJ, Lee MM, Choe G, Kim IA, Kim JH, Kim YJ, Kim HJ. Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review. J Neurooncol. 2011 Jan;101(2):247-54. doi: 10.1007/s11060-010-0249-y. Epub 2010 Jun 5. Review. Erratum in: J Neurooncol. 2011 Jan;101(2):255. Kim, Wook-Ha [corrected to Kim, Wook Ha].</citation>
    <PMID>20526650</PMID>
  </reference>
  <reference>
    <citation>Chi JH, Cachola K, Parsa AT. Genetics and molecular biology of intramedullary spinal cord tumors. Neurosurg Clin N Am. 2006 Jan;17(1):1-5. Review.</citation>
    <PMID>16448901</PMID>
  </reference>
  <reference>
    <citation>McGirt MJ, Goldstein IM, Chaichana KL, Tobias ME, Kothbauer KF, Jallo GI. Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients. Neurosurgery. 2008 Jul;63(1):55-60; discussion 60-1. doi: 10.1227/01.NEU.0000335070.37943.09.</citation>
    <PMID>18728568</PMID>
  </reference>
  <results_reference>
    <citation>Milano MT, Johnson MD, Sul J, Mohile NA, Korones DN, Okunieff P, Walter KA. Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database study. J Neurooncol. 2010 May;98(1):83-92. doi: 10.1007/s11060-009-0054-7. Epub 2009 Nov 7.</citation>
    <PMID>19898743</PMID>
  </results_reference>
  <results_reference>
    <citation>Adams H, Avendaño J, Raza SM, Gokaslan ZL, Jallo GI, Quiñones-Hinojosa A. Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007. Spine (Phila Pa 1976). 2012 May 20;37(12):E727-35. doi: 10.1097/BRS.0b013e31824584c0.</citation>
    <PMID>22609727</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu A, Sankey EW, Bettegowda C, Burger PC, Jallo GI, Groves ML. Poor prognosis despite aggressive treatment in adults with intramedullary spinal cord glioblastoma. J Clin Neurosci. 2015 Oct;22(10):1628-31. doi: 10.1016/j.jocn.2015.05.008. Epub 2015 Jun 30.</citation>
    <PMID>26142051</PMID>
  </results_reference>
  <results_reference>
    <citation>Karsy M, Guan J, Sivakumar W, Neil JA, Schmidt MH, Mahan MA. The genetic basis of intradural spinal tumors and its impact on clinical treatment. Neurosurg Focus. 2015 Aug;39(2):E3. doi: 10.3171/2015.5.FOCUS15143. Review.</citation>
    <PMID>26235020</PMID>
  </results_reference>
  <results_reference>
    <citation>Fakhreddine MH, Mahajan A, Penas-Prado M, Weinberg J, McCutcheon IE, Puduvalli V, Brown PD. Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro Oncol. 2013 Apr;15(4):406-12. doi: 10.1093/neuonc/nos309. Epub 2013 Jan 14.</citation>
    <PMID>23322747</PMID>
  </results_reference>
  <results_reference>
    <citation>Moinuddin FM, Alvi MA, Kerezoudis P, Wahood W, Meyer J, Lachance DH, Bydon M. Variation in management of spinal gliobastoma multiforme: results from a national cancer registry. J Neurooncol. 2019 Jan;141(2):441-447. doi: 10.1007/s11060-018-03054-2. Epub 2018 Nov 20.</citation>
    <PMID>30460627</PMID>
  </results_reference>
  <results_reference>
    <citation>Shows J, Marshall C, Perry A, Kleinschmidt-DeMasters BK. Genetics of Glioblastomas in Rare Anatomical Locations: Spinal Cord and Optic Nerve. Brain Pathol. 2016 Jan;26(1):120-3. doi: 10.1111/bpa.12327.</citation>
    <PMID>26443345</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang M, Iyer RR, Azad TD, Wang Q, Garzon-Muvdi T, Wang J, Liu A, Burger P, Eberhart C, Rodriguez FJ, Sciubba DM, Wolinsky JP, Gokaslan Z, Groves ML, Jallo GI, Bettegowda C. Genomic Landscape of Intramedullary Spinal Cord Gliomas. Sci Rep. 2019 Dec 10;9(1):18722. doi: 10.1038/s41598-019-54286-9.</citation>
    <PMID>31822682</PMID>
  </results_reference>
  <results_reference>
    <citation>Shankar GM, Lelic N, Gill CM, Thorner AR, Van Hummelen P, Wisoff JH, Loeffler JS, Brastianos PK, Shin JH, Borges LF, Butler WE, Zagzag D, Brody RI, Duhaime AC, Taylor MD, Hawkins CE, Louis DN, Cahill DP, Curry WT, Meyerson M. BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016 Jan;131(1):147-50.</citation>
    <PMID>26487540</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Fengzeng Jian</investigator_full_name>
    <investigator_title>director of neurospine department, Xuanwu hospital</investigator_title>
  </responsible_party>
  <keyword>spinal cord astrocytoma; whole-exome sequencing;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

